TACC1 and breast carcinoma: Previous studies have also demonstrated that TACC1 was involved in endocrine therapy (tamoxifen and fulvestrant) resistance in breast cancer 27 and TACC3 was associated with chemoresistance (paclitaxel) in uterine cervical cancer 9.